摘要
恶性肿瘤严重威胁人类健康,近十年间,肿瘤治疗取得了突破性进展。肿瘤细胞膜仿生系统的发展进一步增强了肿瘤靶向策略。来源于自体的肿瘤细胞膜能够消除非生物因素,并显示出高度的生物相容性。此外,肿瘤的快速增殖和易于培养使肿瘤细胞膜比其他类型的生物膜更容易获得。本文首先介绍并回顾细胞膜仿生纳米系统的提出及发展,并且重点描述了在药物递送、光热和成像、肿瘤疫苗方面的应用。其次,对其安全性及可能存在的问题进行讨论。最后提出未来发展的可能方向。
Article PDF
Avoid common mistakes on your manuscript.
References
Barenholz Y, 2012. Doxil®—the first FDA-approved nanodrug: lessons learned. J Control Release, 160(2):117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
Blass E, Ott PA, 2021. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol, 18(4):215–229. https://doi.org/10.1038/s41571-020-00460-2
Burch PA, Croghan GA, Gastineau DA, et al., 2004. Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a phase 2 trial. Prostate, 60(3):197–204. https://doi.org/10.1002/pros.20040
Cao SY, Peterson SM, Müller S, et al., 2021. A membrane protein display platform for receptor interactome discovery. Proc Natl Acad Sci USA, 118(39):e2025451118. https://doi.org/10.1073/pnas.2025451118
Chen L, Qin H, Zhao RF, et al., 2021. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci Transl Med, 13(601): eabc2816. https://doi.org/10.1126/scitranslmed.abc2816
Chen M, Chen M, He JT, 2019. Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA. Artif Cells Nanomed Biotechnol, 47(1):1635–1641. https://doi.org/10.1080/21691401.2019.1608219
Chen Z, Zhao PF, Luo ZY, et al., 2016. Cancer cell membrane-biomimetic nanoparticles for homologous-targeting dualmodal imaging and photothermal therapy. ACS Nano, 10(11):10049–10057. https://doi.org/10.1021/acsnano.6b04695
Fang RH, Hu CMJ, Luk BT, et al., 2014. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett, 14(4):2181–2188. https://doi.org/10.1021/nl500618u
Garber K, 2022. The PROTAC gold rush. Nat Biotechnol, 40(1): 12–16. https://doi.org/10.1038/s41587-021-01173-2
Gong C, Yu X, You B, et al., 2020. Macrophage-cancer hybrid membrane-coated nanoparticles for targeting lung metastasis in breast cancer therapy. J Nanobiotechnology, 18:92. https://doi.org/10.1186/s12951-020-00649-8
Hanahan D, 2022. Hallmarks of cancer: new dimensions. Cancer Discov, 12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059
Hu CMJ, Zhang L, Aryal S, et al., 2011. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA, 108(27):10980–10985. https://doi.org/10.1073/pnas.1106634108
Hu QY, Sun WJ, Qian CE, et al., 2015. Anticancer platelet-mimicking nanovehicles. Adv Mater, 27(44):7043–7050. https://doi.org/10.1002/adma.201503323
Jiang Q, Liu Y, Guo RR, et al., 2019. Erythrocyte-cancer hybrid membrane-camouflaged melanin nanoparticles for enhancing photothermal therapy efficacy in tumors. Biomaterials, 192:292–308. https://doi.org/10.1016/j.biomaterials.2018.11.021
Jiang Y, Krishnan N, Zhou JR, et al., 2020. Engineered cell-membrane-coated nanoparticles directly present tumor antigens to promote anticancer immunity. Adv Mater, 32(30):2001808. https://doi.org/10.1002/adma.202001808
Kantoff PW, Higano CS, Shore ND, et al., 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363(5):411–422. https://doi.org/10.1056/NEJMoa1001294
Keskin DB, Anandappa AJ, Sun J, et al., 2019. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 565(7738):234–239. https://doi.org/10.1038/s41586-018-0792-9
Li AX, Zhao YN, Li YX, et al., 2021. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Deliv, 28(1):1237–1255. https://doi.org/10.1080/10717544.2021.1938757
Li BW, Wang F, Gui LJ, et al., 2018. The potential of biomimetic nanoparticles for tumor-targeted drug delivery. Nanomedicine (Lond), 13(16):2099–2118. https://doi.org/10.2217/nnm-2018-0017
Li RX, He YW, Zhang SY, et al., 2018. Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment. Acta Pharm Sin B, 8(1):14–22. https://doi.org/10.1016/j.apsb.2017.11.009
Lin YY, Chen CY, Ma DL, et al., 2022. Cell-derived artificial nanovesicle as a drug delivery system for malignant melanoma treatment. Biomed Pharmacother, 147:112586. https://doi.org/10.1016/j.biopha.2021.112586
Liu CH, Wang DD, Zhang SY, et al., 2019. Biodegradable biomimic copper/manganese silicate nanospheres for chemodynamic/photodynamic synergistic therapy with simultaneous glutathione depletion and hypoxia relief. ACS Nano, 13(4):4267–4277. https://doi.org/10.1021/acsnano.8b09387
Liu HJ, Wang JF, Wang MM, et al., 2021. Biomimetic nanomedicine coupled with neoadjuvant chemotherapy to suppress breast cancer metastasis via tumor microenvironment remodeling. Adv Funct Mater, 31(25):2100262. https://doi.org/10.1002/adfm.202100262
Liu ZW, Wang FM, Liu XP, et al., 2021. Cell membrane-camouflaged liposomes for tumor cell-selective glycans engineering and imaging in vivo. Proc Natl Acad Sci USA, 118(30):e2022769118. https://doi.org/10.1073/pnas.2022769118
Meng XZ, Wang JJ, Zhou JD, et al., 2021. Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis. Acta Biomater, 127:266–275. https://doi.org/10.1016/j.actbio.2021.03.056
Parodi A, Quattrocchi N, van de Ven AL, et al., 2013. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol, 8(1):61–68. https://doi.org/10.1038/nnano.2012.212
Pei WY, Wan X, Shahzad KA, et al., 2018. Direct modulation of myelin-autoreactive CD4+ and CD8+ T cells in EAE mice by a tolerogenic nanoparticle co-carrying myelin peptide-loaded major histocompatibility complexes, CD47 and multiple regulatory molecules. Int J Nanomed, 13: 3731–3750. https://doi.org/10.2147/IJN.S164500
Tan SW, Wu TT, Zhang D, et al., 2015. Cell or cell membrane-based drug delivery systems. Theranostics, 5(8):863–881. https://doi.org/10.7150/thno.11852
Wang HJ, Liu Y, He RQ, et al., 2020. Cell membrane biomimetic nanoparticles for inflammation and cancer targeting in drug delivery. Biomater Sci, 8(2):552–568. https://doi.org/10.1039/c9bm01392j
Wang J, Zhu MT, Nie GJ, 2021. Biomembrane-based nanostructures for cancer targeting and therapy: from synthetic liposomes to natural biomembranes and membrane-vesicles. Adv Drug Deliv Rev, 178:113974. https://doi.org/10.1016/j.addr.2021.113974
Wu LL, Li Q, Deng JJ, et al., 2021. Platelet-tumor cell hybrid membrane-camouflaged nanoparticles for enhancing therapy efficacy in glioma. Int J Nanomed, 16: 8433–8446. https://doi.org/10.2147/IJN.S333279
Zhao QC, Barclay M, Hilkens J, et al., 2010. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol Cancer, 9:154. https://doi.org/10.1186/1476-4598-9-154
Zhu JY, Zheng DW, Zhang MK, et al., 2016. Preferential cancer cell self-recognition and tumor self-targeting by coating nanoparticles with homotypic cancer cell membranes. Nano Lett, 16(9):5895–5901. https://doi.org/10.1021/acs.nanolett.6b02786
Zhuang J, Holay M, Park JH, et al., 2019. Nanoparticle delivery of immunostimulatory agents for cancer immunotherapy. Theranostics, 9(25):7826–7848. https://doi.org/10.7150/thno.37216
Zitvogel L, Regnault A, Lozier A, et al., 1998. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes. Nat Med, 4(5):594–600. https://doi.org/10.1038/nm0598-594
Zou MZ, Li ZH, Bai XF, et al., 2021. Hybrid vesicles based on autologous tumor cell membrane and bacterial outer membrane to enhance innate immune response and personalized tumor immunotherapy. Nano Lett, 21(20):8609–8618. https://doi.org/10.1021/acs.nanolett.1c02482
Acknowledgments
This work was supported by the National Natural Science Foundation of China (No. U1204819).
Author information
Authors and Affiliations
Contributions
Jun YAO proposed the conjecture and design of the project. Tianjiao PENG studied relevant content and completed the manuscript. Both authors have read and approved the final manuscript, and therefore, have full access to all the data in the study and take responsibility for the integrity and security of the data.
Corresponding author
Additional information
Compliance with ethics guidelines
Tianjiao PENG and Jun YAO declare that they have no conflict of interest.
This article does not contain any studies with human or animal subjects performed by either of the authors.
Rights and permissions
About this article
Cite this article
Peng, T., Yao, J. Development and application of bionic systems consisting of tumor-cell membranes. J. Zhejiang Univ. Sci. B 23, 770–777 (2022). https://doi.org/10.1631/jzus.B2200156
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B2200156